Skip to main content
Enasidenib monotherapy responses in 37% with relapsed/refractory AML and IDH2 mutations
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Enasidenib monotherapy responses in 37% with relapsed/refractory AML and IDH2 mutations
User login
Username
Password
Reset your password
Type
Lead
score